ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Some big deals in the second quarter have raised hopes that takeouts are back.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Regeneron is facing two FDA decisions for its T-cell engagers.
